In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoTherix Inc.

Division of Johnson & Johnson
www.cotherix.com

Latest From CoTherix Inc.

VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug

The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.

BioPharmaceutical Europe

Drug Approvals of 2004

We review new drugs approved by the FDA in 2004, and the ratio of those developed internally to those that were in-licensed.
BioPharmaceutical

Care Capital: VC Post-2001

Care Capital's focus on later-stage programs--driven by its ex-Big Pharma partners' own expertise in more advanced development and marketing--happily coincided with the lower-risk, closer-to-market models which have become fashionable with private and public investors since the 2001 downturn. Does this VC firm have the right model at the right time?
Business Strategies Business Strategies

Biotech Investors: Believing the Dream, Rewarding Phase III IPOs

Valuation Watch: our analysis of US biotech companies that have gone public in the 2003-04 window shows that having a late-stage development project offers private investors the best step-ups.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Exhale Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Donald J Santel, CEO
    James E Pennington, MD, EVP, CMO
    Benson Fong, VP, Corp. Dev.
  • Contact Info
  • CoTherix Inc.
    Phone: (650) 808-6500
    5000 Shoreline Ct.
    Ste. 101
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register